Precigen, Inc. PGEN

US Biotechnology

$4.44 ▼ -6.13% ($-0.29)

🔥 High Short Interest

Open $4.71

Prev Close $4.73

Day Range $4.40 – $4.73

52W Range $3.04 – $8.98

Market Cap $1.70B

Beta 1.09

EPS (TTM) $-0.52

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2013-08-08
Shares Out.	358,040,000
Website	precigen.com/ ↗
Phone	13015569900
Employees	47
Revenue	$74.1M
Gross Profit	$67.6M
Net Income	$35.8M
Free Cash Flow	-$74.3M
Total Assets	$212.1M
Total Liabilities	$128.3M
Equity	$83.8M

About Precigen, Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Precigen, Inc. is a publicly traded company under the ticker symbol PGEN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.